Part,  Chapter, Paragraph

 1   II,     6.Acr    | Multi-Drug Resistance~MMR vaccine~Measles, Mumps and Rubella Vaccine~
 2   II,     6.  3.  5|       covered by the MMR vaccine (measles, mumps and rubella), continue
 3   II,     6.  3.  5|          three quarters of all EU measles cases. The same downward
 4   II,     6.  3.  5|           the goal of eliminating measles and congenital rubella and
 5   II,     6.  3.  5|      threshold, but with over 95% measles vaccine coverage; most of
 6   II,     6.  3.  5|        figure 6.5).~ ~Figure 6.5. Measles (MCV1) vaccine coverage.~ ~
 7   II,     6.  3.  5|           5.2. Viral infections~ ~Measles~ ~Measles is an acute illness
 8   II,     6.  3.  5|      Viral infections~ ~Measles~ ~Measles is an acute illness causes
 9   II,     6.  3.  5|      immunity. The elimination of measles by 2010 (interruption of
10   II,     6.  3.  5|        interruption of indigenous measles transmission) is part of
11   II,     6.  3.  5|         of the strategic plan for measles and congenital rubella infection
12   II,     6.  3.  5|          policy, the incidence of measles in Europe has decreased
13   II,     6.  3.  5|        Figure 6.6).~ ~Figure 6.6. Measles trend in Europe between
14   II,     6.  3.  5|        period. A recrudescence of measles was observed in the Netherlands (
15   II,     9.  2.  3|     alleged damage caused by MMR (measles, mumps and rubella) vaccine.
16   II,     9.  2.  3|     outbreaks of diseases such as measles continue to occur in Europe.
17   II,     9.  2.  8|           Multidrug-Resistant~MMR~Measles, Mumps and Rubella~NICE~
18  III,    10.  3.  3| destruction of the immune system. Measles is an acute illness causes
19  Key,   Ap5.  0.  0|   malnutrition~Malta~marburgvirus~measles~measles-mumps-rubella~megacities~